The Food and Drug Administration for more than 20 years limited dispensing of mifepristone to a subset of specialty offices and clinics because of safety concerns. But it eased restrictions since the start of the COVID-19 pandemic by eliminating the in-person requirement for the pill.
from Section Page News - Modern Healthcare https://ift.tt/5M8yukS
No comments:
Post a Comment